MWNA
SPRB

Marshall Wace North America’s Spruce Biosciences SPRB Stock Holding History

Marshall Wace North America’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-151
Closed -$275K – 1827
2020
Q4 		$275K Buy
+151
New +$250K ﹤0.01% 1184

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Marshall Wace North America's SPRB Position: Q1 2021 in Review

Marshall Wace North America sold out of Spruce Biosciences (SPRB) in Q1 2021, closing a stake of 151 shares — an estimated $275K sold.

Marshall Wace North America first reported a position in SPRB in Q4 2020 and held it in 1 quarter. The position peaked at $275K in Q4 2020. 40 funds tracked by Wall St. Rank hold SPRB as of Q1 2021.

  • Marshall Wace North America reported no remaining Spruce Biosciences position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 151 Spruce Biosciences shares in Q1 2021, an estimated $275K.
  • Marshall Wace North America first reported a position in Spruce Biosciences in Q4 2020 and held it in 1 quarter.
  • Marshall Wace North America's Spruce Biosciences position peaked at $275K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.